Antimicrobial Therapy Options for Subclinical Mycoplasma Control in Poultry

Subclinical infections caused by Mycoplasma gallisepticum (MG) and Mycoplasma synoviae (MS) continue to compromise poultry productivity worldwide. Even without visible clinical signs, these pathogens reduce feed efficiency, egg production, and flock uniformity, leading to substantial hidden economic losses¹. 

Understanding Subclinical Mycoplasma Infections 

Subclinical MG/MS infections present with minimal or no respiratory signs but can cause measurable reductions in performance, including^1,2,3: 

• Reduced FCR 

• 1–15% decline in egg production 

• Increased sensitivity to secondary respiratory infections 

• Decreased shell quality and hatchability 

Early serological or PCR detection is essential for preventing long-term performance loss¹. 

Step 1: Confirmatory Diagnosis and Flock Assessment 

Accurate diagnosis prevents unnecessary antimicrobial use and ensures targeted intervention. Recommended steps include^2,3: 

• Routine ELISA or rapid plate agglutination tests 

• PCR confirmation for higher specificity 

• Culture and susceptibility testing when possible 

• Performance benchmarking (FCR, egg output) 

These practices align with modern antimicrobial stewardship guidelines. 

Step 2: Deciding Whether to Treat 

Antimicrobial treatment may be justified when: 

• Infection is confirmed 

• Production losses are documented 

• Risk of spread to other flocks is high 

• Vertical transmission risk is present (especially breeders) 

• Cost-benefit analysis supports treatment 

This decision must always consider regulations and withdrawal periods. 

Step 3: Selecting Appropriate Antimicrobials  

Selecting antimicrobials for Mycoplasma gallisepticum (MG) and Mycoplasma synoviae (MS) should be based on susceptibility patterns, regional resistance trends, product labels approved in India, and veterinary oversight. Because mycoplasmas lack a cell wall, β-lactam antibiotics are ineffective. However, several non–cell-wall–targeting antimicrobial classes continue to show in-vitro activity⁵. 

Macrolides 

Macrolides such as tylosin, tilmicosin, and tylvalosin have been widely used for MG and MS control because of their excellent tissue penetration. Recent MIC studies from India and Southeast Asia indicate lower MIC values for tylvalosin, with increasing MICs reported for tylosin and tilmicosin in some regions. These findings highlight the importance of local resistance monitoring before choosing a macrolide. 

Tetracyclines 

Drugs like chlortetracycline and doxycycline remain cost-effective broad-spectrum options. Surveillance data show consistently low MICs for both agents, supporting their continued use where susceptibility is confirmed. Doxycycline often demonstrates better absorption and intracellular penetration, making it a preferred option in some field settings. 

Fluoroquinolones 

Fluoroquinolones (e.g., enrofloxacin) have strong activity against mycoplasmas, but resistance is increasing rapidly, and their use in food-producing poultry is heavily regulated under India’s AMR action frameworks. They should be used only under strict veterinary justification and in alignment with national regulatory guidance. 

Pleuromutilins 

Tiamulin remains one of the most effective options for resistant MG/MS strains, with consistently low MICs across multiple studies. However, it must not be used concurrently with ionophore anticoccidials due to the risk of toxicity. Tylvalosin (a newer macrolide) and tiamulin are considered among the most reliable drugs where permitted.  

Step 4: Implementing Treatment  

Successful treatment requires more than selecting an appropriate antimicrobial—it depends on correct field implementation and adherence to Indian regulatory requirements. 

Key considerations include: 

• Following label instructions of India-approved veterinary products 

• Ensuring that dosing calculations are based on actual flock weight 

• Verifying accurate calibration of dosing and water-medication systems 

• Monitoring water intake, especially during heat stress or disease outbreaks 

• Avoiding interruptions or dilution errors during medication periods 

• Maintaining complete regulatory and withdrawal documentation as per FSSAI and DAHD guidelines 

• Reinforcing biosecurity, vaccination, and environmental management, which directly influence antimicrobial success 

Step 5: Monitoring Treatment Efficacy 

Post-treatment follow-up includes: 

• PCR or serology 2–4 weeks post-therapy 

• Tracking FCR, egg production, uniformity 

• Pre–post economic comparison 

Step 6: Long-Term Control Strategy 

Mycoplasma control program in poultry must integrate biosecurity, immunoprophylaxis, monitoring, and prudent antimicrobial stewardship. The following components form the foundation of long-term management, especially in breeder and layer operations where vertical and horizontal transmission have major economic impact. 

1. Strengthen Biosecurity⁵ 

Preventing pathogen introduction remains the most cost-effective control measure. 

• Controlled farm access with strict visitor protocols 

• Dedicated clothing, footwear, and equipment for each house 

• Effective cleaning and disinfection between cycles 

• All-in/all-out placement to limit cross-flock transmission 

• Control of multi-age farming and wild bird exposure 

2. Vaccination (Immunoprophylaxis)⁵ 

Used primarily in long-living flocks to reduce egg transmission, respiratory colonization, and field-strain circulation. 

a. Live Attenuated Vaccines (MG/MS) 

• F-strain, 6/85, ts-11, K-strain, and MS-H vaccines 

• Provide strong local respiratory immunity 

• Useful for displacing virulent field strains 

• ts-11 and 6/85 produce minimal post-vaccination reactions and are preferred in sensitive flocks 

• K-strain shows higher efficacy with minimal risk of spread 

b. Inactivated Vaccines 

• Administered intramuscularly or subcutaneously 

• Reduce egg production losses, egg-transmissible infections, and ovarian regression 

• No risk of transmission or reversion to virulence 

• Limited by cost and need for individual bird administration 

c. Recombinant (rFP-MG) Vaccines 

• Vector vaccines expressing MG antigens 

• Lower risk of introducing live MG into the flock 

• Efficacy varies; commercial use is more limited 

3. Ongoing Monitoring 

Regular flock assessment helps detect early infection and guide interventions. 

• Routine serology (ELISA, HI) 

• PCR surveillance of breeder replacements 

• Post-vaccination response monitoring 

• Flock performance audits and culling of chronic carriers 

• Early action on respiratory signs or drops in production 

4. Strategic Antimicrobial Rotation⁵ 

Rotation of antimicrobial classes helps reduce selection pressure and maintain effectiveness. 

• Alternate between macrolides, tetracyclines, pleuromutilins, etc. 

• Avoid repeated use of the same drug class across cycles 

• Use antimicrobials only when clinically indicated 

5. Antimicrobial Resistance (AMR) Considerations 

Responsible antimicrobial use is critical to safeguard both flock health and public health. 

• Treat only after confirmed diagnosis and differentiation from other respiratory pathogens 

• Use MIC-based susceptibility results to guide molecule selection 

• Complete prescribed treatment courses—avoid premature discontinuation 

• Avoid subtherapeutic or frequent low-level dosing 

• Continuously monitor for resistance development, especially to fluoroquinolones and macrolides 

Conclusion 

Subclinical MG/MS infections silently erode flock productivity. With accurate diagnosis, appropriate antimicrobial selection, and responsible implementation, veterinarians can significantly reduce economic losses. Sustainable success depends on integrating antimicrobials with biosecurity, vaccination, monitoring, and antimicrobial stewardship—ensuring long-term protection against both disease and antimicrobial resistance. 

References 

1. Kursa O, Tomczyk G, Sieczkowska A, Kostka S, Sawicka-Durkalec A. Mycoplasma gallisepticum and Mycoplasma synoviae in Turkeys in Poland. Pathogens. 2024 Jan 15;13(1):78.  

2. Abdelrahman A, Shany S, Dardeer M, Hassan K, Ali A, ElKady M. Avian Mycoplasma gallisepticum and Mycoplasma synoviae: advances in diagnosis and control. Ger. J. Vet. Res. 2021;1(2):46-55. 

3. Al-Baqir A, Hassanin O, Al-Rasheed M, Ahmed MS, Mohamed MH, El Sayed MS, Megahed M, El-Demerdash A, Hashem Y, Eid A. Mycoplasmosis in poultry: an evaluation of diagnostic schemes and molecular analysis of Egyptian Mycoplasma gallisepticum strains. Pathogens. 2023 Sep 5;12(9):1131. 

4. Huang A, Wang S, Guo J, Gu Y, Li J, Huang L, Wang X, Tao Y, Liu Z, Yuan Z, Hao H. Prudent use of tylosin for treatment of mycoplasma gallisepticum based on its clinical breakpoint and lung microbiota shift. Frontiers in Microbiology. 2021 Sep 9;12:712473. 
5. Yadav JP, Tomar P, Singh Y, Khurana SK. Insights on Mycoplasma gallisepticum and Mycoplasma synoviae infection in poultry: a systematic review. Animal Biotechnology. 2022 Dec 12;33(7):1711-20.